Publication:
Eltrombopag : How secure in triple therapy of HCV ?

dc.contributor.authorKayar, Yusuf
dc.contributor.authorDanalioglu, Ahmet
dc.contributor.authorKocaman, Orhan
dc.contributor.authorBaysal, Birol
dc.contributor.authorŞENTÜRK, HAKAN
dc.contributor.institutionauthorŞENTÜRK, HAKAN
dc.date.accessioned2020-10-29T14:39:51Z
dc.date.available2020-10-29T14:39:51Z
dc.date.issued2015-10-01T00:00:00Z
dc.description.abstractTriple therapy of hepatitis C usually leads to some hematological and dermatological side effects. Thrombocytopenia is one of the most common side effects that are encountered during triple therapy. Eltrombopag was approved for the treatment of patients with chronic hepatitis C and thrombocytopenia to allow the initiation and maintenance of interferon based therapies. During eltrombopag therapy, some side effects like headache, abdominal pain, and some complications such as portal vein thrombosis, deep vein thrombosis and arterial thrombosis were observed more frequently than placebo. We described here a patient who developing thrombosis secondary to eltrombopag in receiving triple therapy.
dc.identifier.citationKayar Y., Danalioglu A., Kocaman O., Baysal B., ŞENTÜRK H., -Eltrombopag : How secure in triple therapy of HCV ?-, ACTA GASTRO-ENTEROLOGICA BELGICA, cilt.78, ss.445-446, 2015
dc.identifier.scopus84953258837
dc.identifier.urihttp://hdl.handle.net/20.500.12645/25365
dc.identifier.wosWOS:000373452000017
dc.titleEltrombopag : How secure in triple therapy of HCV ?
dc.typeArticle
dspace.entity.typePublication
local.avesis.id283fdf66-2915-4549-8e86-81e3e459ee26
local.publication.goal03 - Sağlık ve Kaliteli Yaşam
local.publication.isinternational1
relation.isAuthorOfPublication278fcf63-3b92-4368-bff6-f140ebd9aeb3
relation.isAuthorOfPublication.latestForDiscovery278fcf63-3b92-4368-bff6-f140ebd9aeb3
relation.isGoalOfPublication9c198c48-b603-4e2f-8366-04edcfc1224c
relation.isGoalOfPublication.latestForDiscovery9c198c48-b603-4e2f-8366-04edcfc1224c
Files